Table 2:

Effect of intervention on delaying the onset of primary outcomes, event-free years gained, and numbers needed to treat during the 30-year follow-up

	Median delay, years (95% CI)	Mean number of event-free years (95% CI)	Number needed to treat (95% CI)
Diabetes	3.96 (1.25 to 6.67; p=0.0042)	4.07 (1.46 to 6.68; p=0.0022)	10 (7 to 23)
CVD events	4.64 (1.05 to 8.22; p=0.011)	1.77 (0.18 to 3.36; p=0.029)	9 (5 to 36)
Composite microvascular disease outcome	5.17 (−056 to 10.90; p=0.077)	0.96 (−0.12 to 2.03; p=0.080)	10 (5 to 193)
CVD deaths	7.25 (−0.18 to 14.67; p=0.056)	1.06 (0.10 to 2.23; p=0.074)	10 (5 to 72)
All-cause mortality	4.82 (1.48 to 8.15; p=0.0047)	1.44 (0.20 to 2.68; p=0.023)*	10 (6 to 25)

Cardiovascular disease (CVD) events were defined as non-fatal or fatal myocardial infarction or sudden death, hospital admission due to heart failure, or non-fatal or fatal stroke. Composite microvascular disease was defined as an aggregate of retinopathy, nephropathy, and neuropathy. CVD deaths were defined as death due to myocardial infarction, sudden death, heart failure, or stroke.

^*Mean increase in life-expectancy.